US EditionPublished • loading... • Updated
Green Light to Astrazeneca Therapy for a Tumor with Very Poor Prognosis
Summary by redaccionmedica.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Imfinzi (durvalumab), from AstraZeneca, has been approved in the European Union (EU) for the treatment of adult patients with gastric adenocarcinoma and resectable gastroesophageal junction (UGE), early and locally advanced (stages II, III, IVA). The approved regimen consists of the combination of the drug with standard FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin and docetaxel). The protocol includes two cycles of the combination be…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
